Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Assets (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Current Assets for 4 consecutive years, with $675.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 21.74% to $675.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $675.7 million through Dec 2025, down 21.74% year-over-year, with the annual reading at $675.7 million for FY2025, 21.74% down from the prior year.
  • Current Assets hit $675.7 million in Q4 2025 for NewAmsterdam Pharma, down from $732.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $863.4 million in Q4 2024 to a low of $346.8 million in Q4 2023.
  • Historically, Current Assets has averaged $603.4 million across 4 years, with a median of $581.8 million in 2024.
  • Biggest five-year swings in Current Assets: fell 24.15% in 2023 and later soared 148.97% in 2024.
  • Year by year, Current Assets stood at $457.2 million in 2022, then fell by 24.15% to $346.8 million in 2023, then skyrocketed by 148.97% to $863.4 million in 2024, then fell by 21.74% to $675.7 million in 2025.
  • Business Quant data shows Current Assets for NAMS at $675.7 million in Q4 2025, $732.3 million in Q3 2025, and $769.8 million in Q2 2025.